{"id":397216,"date":"2020-12-10T08:03:17","date_gmt":"2020-12-10T13:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=397216"},"modified":"2020-12-10T08:03:17","modified_gmt":"2020-12-10T13:03:17","slug":"acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/","title":{"rendered":"Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\u20ac1.18 billion acquisition provides for significant returns to PPF Group as NBE\u2019s largest shareholder<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align:justify\">SOTIO, a clinical stage immuno-oncology company, and a member of PPF Group, continues development of two ADC products under the collaboration with NBE<\/li>\n<\/ul>\n<p align=\"justify\">PRAGUE, Czech Republic, Dec.  10, 2020  (GLOBE NEWSWIRE) &#8212; PPF Group, an international investment group, today announced the signing of a\u00a0binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC\u2122 platform to develop potential best-in-class antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The lead program NBE-002, an iADC targeting ROR1, entered the Phase 1 clinical testing in 2020.<\/p>\n<p align=\"justify\">The transaction is worth up to \u20ac1.18 billion, and is comprised of an upfront payment to NBE\u2019s shareholders as well as contingent clinical and regulatory milestones. Transaction is subject to customary closing conditions.<\/p>\n<p align=\"justify\">PPF Group initially invested into NBE four years ago,\u00a0and was NBE\u2019s largest shareholder at the time of the acquisition.<\/p>\n<p align=\"justify\">NBE-Therapeutics, as part of Boehringer, will remain at its campus in Basel, Switzerland and will continue to support the existing partnership with PPF-owned SOTIO on SOTIO\u2019s two preclinical-stage ADC programs, SO-N102 and SO-N107. SOTIO is focused on developing clinical stage immuno-oncology therapeutics and directing the biotechnology investments of PPF.<\/p>\n<p align=\"justify\">\n        <em>\u201cWe\u2019d like congratulate the NBE team on this major achievement and express our sincere gratitude to everybody who supported this journey over the last years,\u201d<\/em> said <strong>Jens Hennecke<\/strong>, Ph.D., chief business officer of SOTIO and a member of the board of directors of NBE. <em>\u201cFrom the beginning, we have been excited about the prospect of NBE\u2019s iADC platform. This landmark acquisition, one of the largest of its kind in Europe, provides an important validation for our approach and points to the significant value of our two ADC candidates, SO-N102 and SO-N107. We look forward to continuing our partnership with NBE-Therapeutics to advance SO-N102 into the clinics by the end of 2021 and continue the preclinical activities for SO-N107.\u201d<\/em>\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Ladislav Barton\u00ed\u010dek<\/strong>, shareholder of PPF Group, added, <em>\u201cWe are excited for the future of NBE-Therapeutics as part of Boehringer Ingelheim. Boehringer will now use its expertise and commitment to oncology research to realize the potential of the iADC platform to create best-in-class ADC therapies for the benefit of patients. This acquisition validates our business model of investing into companies with potentially game-changing platforms and products.\u201d <\/em>\u00a0<\/p>\n<p align=\"justify\">Notes for Editors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jm9DKPcYxRlwVgdQcyGPIgX1IlNsczM64zrQbgVpJCJjy8miT0Y5GjEj2FxUfScvIzCidNL_nueQe4SQWcW-xw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>PPF\u00a0Group<\/u><\/strong><\/a> invests in multiple market segments including financial services, telecommunications, media, biotechnology, real estate and mechanical engineering. PPF Group\u2019s growth rests on the development of traditional and new industries, the building of modern infrastructure, the digital economy and linking up Czech talent and capabilities with global opportunities. PPF Group\u2019s reach spans from Europe to North America and across Asia. The Group owns assets worth EUR\u00a044 billion and employs 98,000 people globally (<em>as\u00a0at 30 June 2020)<\/em>. PPF pays income taxes in each of 25 countries in which it operates and generates profit.<\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vj6tYtnHeAC_RFq-UtY5Ue3vjyD17VKanrgOThL2NPI86YtMbKLuQd9-uuGu3HmWT5nKtMtXAs6VzzCuJftgMQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.ppf.eu<\/a><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FsVGe7FLQ37hoOJF8ABVhWWFVLUGf8uuuSPZvMIJxc9NRo0ShcHSHnXM93i1yqA_5gXhMYE9QWab94jc7gCVZJocvur_dxv_FfROMEVazgc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.twitter.com\/ppfgroup<\/a><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6fNQGJsDDrESLRIJUZHH0udY--LNhqXKkxpwNpT13feTnoQFzmb5MwKnUaSttJ5zQ3O2Log6uqRZpKaao9KmfDV1fmbJFuv-tpI70X0n1cPYG95ofWE0cZgBU23l1SUk\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.linkedin.com\/company\/ppf<\/a>\n      <\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p6ksE98AUN6Gcem4GaTHnpSQz-xg4yGztPrPWRP0qtR5OWtZ3B88JoVyO3OhCx0W\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <u>SOTIO<\/u><br \/>\n          <\/strong><br \/>\n        <\/a> is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO\u2019s robust clinical pipeline includes a differentiated superagonist of\u00a0the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group. For more information, please visit the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BGMrhUmIvfL2LCjWc4htg87LV4VRUfzqxoVsJHIc4-jn-rezkiVJzbxv3Z6Rvyt0_poTqtCcn3uG8r9yiXw-AA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">sotio.com<\/a>. SOTIO is a registered trademark of SOTIO a.s. in selected countries.<\/p>\n<table style=\"border-collapse: collapse;margin-left:0px;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:30%;width:30%;min-width:30%;vertical-align: top\">\n            <strong>Contact:<\/strong>\n          <\/td>\n<td style=\"max-width:70%;width:70%;min-width:70%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>PPF<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">\n            <strong>SOTIO<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Jitka Tkadlecov\u00e1<\/td>\n<td style=\"vertical-align: top\">Richard Kapsa<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">PPF Group Spokeswoman<\/td>\n<td style=\"vertical-align: top\">Head of Communication<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">T +420\u00a0224\u00a0174\u00a0704<\/td>\n<td style=\"vertical-align: top\">T +420 224 174 448<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <a href=\"mailto:spokesperson@ppf.eu\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">spokesperson@ppf.eu<\/a>\n          <\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"mailto:kapsa@sotio.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">kapsa@sotio.com<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTkzMCMzODY0NzY3IzUwMDA3NjI2NQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/252127f9-e6b0-45bf-98c6-62120bdda160\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u20ac1.18 billion acquisition provides for significant returns to PPF Group as NBE\u2019s largest shareholder SOTIO, a clinical stage immuno-oncology company, and a member of PPF Group, continues development of two ADC products under the collaboration with NBE PRAGUE, Czech Republic, Dec. 10, 2020 (GLOBE NEWSWIRE) &#8212; PPF Group, an international investment group, today announced the signing of a\u00a0binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC\u2122 platform to develop potential best-in-class antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The lead program NBE-002, an iADC targeting ROR1, entered the Phase 1 clinical testing in 2020. The transaction is worth up to \u20ac1.18 billion, and is comprised of an upfront payment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-397216","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u20ac1.18 billion acquisition provides for significant returns to PPF Group as NBE\u2019s largest shareholder SOTIO, a clinical stage immuno-oncology company, and a member of PPF Group, continues development of two ADC products under the collaboration with NBE PRAGUE, Czech Republic, Dec. 10, 2020 (GLOBE NEWSWIRE) &#8212; PPF Group, an international investment group, today announced the signing of a\u00a0binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC\u2122 platform to develop potential best-in-class antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The lead program NBE-002, an iADC targeting ROR1, entered the Phase 1 clinical testing in 2020. The transaction is worth up to \u20ac1.18 billion, and is comprised of an upfront payment &hellip; Continue reading &quot;Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-10T13:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTkzMCMzODY0NzY3IzUwMDA3NjI2NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group\",\"datePublished\":\"2020-12-10T13:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/\"},\"wordCount\":616,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTkzMCMzODY0NzY3IzUwMDA3NjI2NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/\",\"name\":\"Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTkzMCMzODY0NzY3IzUwMDA3NjI2NQ==\",\"datePublished\":\"2020-12-10T13:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTkzMCMzODY0NzY3IzUwMDA3NjI2NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTkzMCMzODY0NzY3IzUwMDA3NjI2NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/","og_locale":"en_US","og_type":"article","og_title":"Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group - Market Newsdesk","og_description":"\u20ac1.18 billion acquisition provides for significant returns to PPF Group as NBE\u2019s largest shareholder SOTIO, a clinical stage immuno-oncology company, and a member of PPF Group, continues development of two ADC products under the collaboration with NBE PRAGUE, Czech Republic, Dec. 10, 2020 (GLOBE NEWSWIRE) &#8212; PPF Group, an international investment group, today announced the signing of a\u00a0binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC\u2122 platform to develop potential best-in-class antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The lead program NBE-002, an iADC targeting ROR1, entered the Phase 1 clinical testing in 2020. The transaction is worth up to \u20ac1.18 billion, and is comprised of an upfront payment &hellip; Continue reading \"Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-10T13:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTkzMCMzODY0NzY3IzUwMDA3NjI2NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group","datePublished":"2020-12-10T13:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/"},"wordCount":616,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTkzMCMzODY0NzY3IzUwMDA3NjI2NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/","name":"Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTkzMCMzODY0NzY3IzUwMDA3NjI2NQ==","datePublished":"2020-12-10T13:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTkzMCMzODY0NzY3IzUwMDA3NjI2NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTkzMCMzODY0NzY3IzUwMDA3NjI2NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acquisition-agreement-with-boehringer-ingelheim-for-nbe-therapeutics-marks-first-major-biotech-exit-for-ppf-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=397216"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397216\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=397216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=397216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=397216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}